News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
320,151 Results
Type
Article (11310)
Company Profile (46)
Press Release (308795)
Multimedia
Podcasts (23)
Webinars (6)
Section
Business (105588)
Career Advice (567)
Deals (18582)
Drug Delivery (23)
Drug Development (25983)
Employer Resources (42)
FDA (6476)
Job Trends (5800)
News (157478)
Policy (11190)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (645)
Accelerated approval (10)
Adcomms (5)
Allergies (27)
Alliances (23847)
ALS (48)
Alzheimer's disease (660)
Antibody-drug conjugate (ADC) (69)
Approvals (6607)
Artificial intelligence (238)
Autoimmune disease (40)
Automation (15)
Bankruptcy (137)
Best Places to Work (4407)
BIOSECURE Act (1)
Biosimilars (53)
Biotechnology (37)
Bladder cancer (51)
Brain cancer (17)
Breast cancer (237)
Cancer (1725)
Cardiovascular disease (118)
Career advice (494)
Career pathing (6)
CAR-T (78)
CDC (5)
Celiac Disease (1)
Cell therapy (218)
Cervical cancer (17)
Clinical research (22191)
Collaboration (701)
Company closure (1)
Compensation (396)
Complete response letters (16)
COVID-19 (858)
CRISPR (18)
C-suite (435)
Cystic fibrosis (41)
Data (1930)
Decentralized trials (1)
Denatured (1)
Depression (35)
Diabetes (124)
Diagnostics (6378)
Digital health (20)
Diversity (2)
Diversity, equity & inclusion (16)
Drug discovery (61)
Drug pricing (26)
Drug shortages (7)
Duchenne muscular dystrophy (61)
Earnings (49423)
Editorial (12)
Employer branding (10)
Employer resources (44)
Events (50227)
Executive appointments (538)
FDA (7584)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (5)
Frontotemporal dementia (9)
Funding (559)
Gene editing (34)
Generative AI (15)
Gene therapy (154)
GLP-1 (254)
Government (1117)
Guidances (233)
Healthcare (7517)
HIV (15)
Huntington's disease (17)
IgA nephropathy (16)
Immunology and inflammation (71)
Immuno-oncology (15)
Indications (25)
Infectious disease (923)
Inflammatory bowel disease (57)
Inflation Reduction Act (4)
Influenza (30)
Intellectual property (55)
Interviews (64)
IPO (8983)
IRA (6)
Job creations (1520)
Job search strategy (450)
JPM (14)
Kidney cancer (10)
Labor market (15)
Layoffs (170)
Leadership (10)
Legal (2868)
Liver cancer (43)
Longevity (4)
Lung cancer (210)
Lymphoma (132)
Machine learning (9)
Management (12)
Manufacturing (256)
MASH (70)
Medical device (5706)
Medtech (5725)
Mergers & acquisitions (10124)
Metabolic disorders (363)
Multiple sclerosis (76)
NASH (8)
Neurodegenerative disease (125)
Neuropsychiatric disorders (23)
Neuroscience (1072)
Neurotech (1)
NextGen: Class of 2026 (2295)
Non-profit (1298)
Now hiring (9)
Obesity (165)
Opinion (72)
Ovarian cancer (50)
Pain (33)
Pancreatic cancer (75)
Parkinson's disease (77)
Partnered (10)
Patents (100)
Patient recruitment (131)
Peanut (11)
People (31901)
Pharmaceutical (8)
Pharmacy benefit managers (4)
Phase 1 (6694)
Phase 2 (9515)
Phase 3 (7910)
Pipeline (2464)
Policy (37)
Postmarket research (928)
Preclinical (2605)
Press Release (66)
Prostate cancer (116)
Psychedelics (8)
Radiopharmaceuticals (183)
Rare diseases (248)
Real estate (2575)
Recruiting (15)
Regulatory (8511)
Reports (23)
Research institute (734)
Resumes & cover letters (82)
Rett syndrome (23)
RNA editing (2)
RSV (6)
Schizophrenia (56)
Series A (91)
Series B (78)
Service/supplier (1)
Sickle cell disease (13)
Special edition (7)
Spinal muscular atrophy (91)
Sponsored (12)
Startups (1584)
Stomach cancer (7)
Supply chain (25)
Tariffs (31)
The Weekly (22)
Vaccines (172)
Venture capital (24)
Weight loss (85)
Women's health (25)
Date
Today (4)
Last 7 days (215)
Last 30 days (867)
Last 365 days (12225)
2026 (1101)
2025 (12536)
2024 (15313)
2023 (18123)
2022 (25798)
2021 (26567)
2020 (25165)
2019 (18329)
2018 (14241)
2017 (14539)
2016 (13693)
2015 (17147)
2014 (13395)
2013 (11158)
2012 (11991)
2011 (12617)
2010 (11997)
Location
Africa (318)
Alabama (27)
Alaska (3)
Arizona (146)
Arkansas (3)
Asia (16214)
Australia (2714)
California (4727)
Canada (1451)
China (255)
Colorado (223)
Connecticut (238)
Delaware (83)
Europe (39708)
Florida (702)
Georgia (110)
Idaho (26)
Illinois (324)
India (23)
Indiana (132)
Iowa (15)
Japan (202)
Kansas (48)
Kentucky (22)
Louisiana (12)
Maine (69)
Maryland (481)
Massachusetts (3432)
Michigan (183)
Minnesota (275)
Mississippi (2)
Missouri (67)
Montana (23)
Nebraska (16)
Nevada (51)
New Hampshire (34)
New Jersey (1252)
New Mexico (21)
New York (1247)
North Carolina (665)
North Dakota (9)
Northern California (2451)
Ohio (149)
Oklahoma (10)
Oregon (14)
Pennsylvania (686)
Puerto Rico (1)
Rhode Island (23)
South America (424)
South Carolina (21)
Southern California (1733)
Tennessee (82)
Texas (720)
United States (16630)
Utah (218)
Vermont (1)
Virginia (136)
Washington D.C. (26)
Washington State (416)
West Virginia (3)
Wisconsin (91)
Wyoming (2)
320,151 Results for "roche diagnostics corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Roche Keeps the Deals Coming With up to $1.7B SangeneBio RNAi Pact
The alliance will add to Roche’s RNAi efforts, which include the hypertension candidate zilbesiran, partnered with Alnylam under a July 2023 agreement.
February 3, 2026
·
1 min read
·
Tristan Manalac
Breast cancer
Roche’s Oral SERD Cuts Death Risk by 30% in Early-Stage Breast Cancer
While overall survival remains immature, results so far show a clear trend in favor of Roche’s giredestrant.
December 11, 2025
·
2 min read
·
Tristan Manalac
Earnings
Roche Plans To Go Toe-to-Toe With Novo, Lilly in Obesity
Roche aims to become a “top three player” in obesity, Teresa Graham, CEO of the group’s Pharma unit, said Thursday during a presentation of the company’s full-year 2025 earnings.
January 29, 2026
·
2 min read
GLP-1
Roche’s 22% Weight Loss Benefit Seals GLP-1’s Phase III Plans, Boosts Zealand Combo
Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.
January 27, 2026
·
2 min read
·
Annalee Armstrong
Lung cancer
Roche Spends $570M on Another ADC Agreement With China’s MediLink
Roche first partnered with MediLink in January 2024, likewise for an antibody-drug conjugate for solid tumors.
January 9, 2026
·
1 min read
·
Tristan Manalac
Podcast
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as Health Secretary Robert F. Kennedy’s anti-vaccine policies and rhetoric continues; and embattled gene therapy maker Sarepta announces new data in Duchenne muscular dystrophy.
January 28, 2026
·
1 min read
·
Heather McKenzie
Manufacturing
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
Genentech, a member of the Roche Group, plans to open the facility in 2029 to ramp up capacity to make obesity candidates, including the dual GLP-1/GIP receptor agonist CT-388.
January 21, 2026
·
2 min read
·
Nick Paul Taylor
Obesity
Roche Clears Obesity Pill Legal Concerns With Structure Patent Agreement
The agreement, which BMO Capital Markets called a “mild positive” for Structure, appears to address Roche’s concerns about the composition of investigational weight loss drug CT-996.
January 6, 2026
·
2 min read
·
Tristan Manalac
Autoimmune disease
Roche’s Gazyva Expands Out of Cancer With FDA Approval for Lupus
The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of action gives it activity in improving kidney conditions in patients with lupus nephritis.
October 20, 2025
·
2 min read
·
Dan Samorodnitsky
Artificial intelligence
Roche Makes Good on Dealmaking Promise With $1.1B Caris Cancer Collab
Roche CEO Thomas Schinecker said during the company’s Q3 call that it is “not done” with deals—a promise he delivered on with Tuesday’s solid tumor pact with AI-focused Caris Life Sciences.
December 17, 2025
·
1 min read
·
Tristan Manalac
1 of 32,016
Next
